PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRituximab
Rituxan, Mabthera(rituximab)
Blitzima, MabThera, Riabni, Rituxan, Rixathon, Riximyo, Ruxience, Truxima (rituximab) is an antibody pharmaceutical. Rituximab was first approved as Rituxan on 1997-11-26. It is used to treat b-cell lymphoma, granulomatosis with polyangiitis, lymphoid leukemia, mantle-cell lymphoma, and microscopic polyangiitis amongst others in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia, microscopic polyangiitis, non-hodgkin lymphoma, pemphigus, and rheumatoid arthritis. The pharmaceutical is active against B-lymphocyte antigen CD20.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
nervous system diseasesD009422
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Riabni, Rituxan, Ruxience, Truxima (discontinued: Rituxan)
Combinations
Rituxan hycela
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Rituximab
Tradename
Proper name
Company
Number
Date
Products
RituxanrituximabGenentechN-103705 RX1997-11-26
2 products
Show 1 discontinued
Hyaluronidase human
+
Rituximab
Tradename
Proper name
Company
Number
Date
Products
Rituxan Hycelarituximab and hyaluronidase humanGenentechN-761064 RX2017-06-22
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
riabniBiologic Licensing Application2025-09-12
rituxanBiologic Licensing Application2025-01-06
rituxan hycelaBiologic Licensing Application2025-12-15
ruxienceBiologic Licensing Application2025-06-18
truximaBiologic Licensing Application2025-06-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
rheumatoid arthritisEFO_0000685D001172M06.9
mantle-cell lymphoma—D020522C83.1
b-cell lymphoma—D016393—
lymphoid leukemia—D007945C91
granulomatosis with polyangiitisEFO_0005297D014890M31.3
microscopic polyangiitisEFO_1000784D055953M31.7
Agency Specific
FDA
EMA
Expiration
Code
rituximab, Rituxan, Genentech, Inc.
2026-09-27Orphan excl.
rituximab / hyaluronidase human, Rituxan Hycela, Genentech, Inc.
2024-06-22Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XC: Monoclonal antibodies, antineoplastic
— L01XC02: Rituximab
HCPCS
Code
Description
J9311
Injection, rituximab 10 mg and hyaluronidase
J9312
Injection, rituximab, 10 mg
Q5115
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
Q5119
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
Q5123
Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
Clinical
Clinical Trials
2720 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.92425951601692986
Large b-cell lymphoma diffuseD016403—C83.313833189445527
Non-hodgkin lymphomaD008228—C85.9168311911131523
B-cell lymphomaD016393——12924053634391
B-cell chronic lymphocytic leukemiaD015451—C91.111319353528344
Follicular lymphomaD008224—C828917676123315
LeukemiaD007938—C957315430722256
Mantle-cell lymphomaD020522—C83.1721612818231
Lymphoid leukemiaD007945—C91398523816156
B-cell lymphoma marginal zoneD018442—C88.443902328142
Show 76 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——367019—4110
NeoplasmsD009369—C8038385—468
Large-cell lymphoma immunoblasticD016400——16301—138
Myelodysplastic syndromesD009190—D4610202—330
Myeloid leukemia acuteD015470—C92.09183——27
SyndromeD013577——8193—326
Graft vs host diseaseD006086—D89.815173—225
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—2151——17
SclerosisD012598——263—615
Hemolytic anemia autoimmuneD000744EFO_1001264D59.10—85—214
Show 63 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.02118——235
Hematologic neoplasmsD019337——1714——228
Hairy cell leukemiaD007943—C91.4917——223
T-cell lymphomaD016399——1112——220
Plasma cell neoplasmsD054219——910——118
Central nervous system neoplasmsD016543——1011——118
Intraocular lymphomaD064090——911——117
Lymphomatoid granulomatosisD008230—C83.8812———15
T-cell lymphoma peripheralD016411——78——214
Prolymphocytic leukemiaD015463——78———13
Show 216 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neoplasm metastasisD009362EFO_0009708—3————3
Psoriatic arthritisD015535EFO_0003778L40.51———23
EncephalitisD004660——1———23
GliomaD005910EFO_0000520—2————2
AdenocarcinomaD000230——1————1
TransplantationD014180——1————1
DiseaseD004194EFO_0000408R691————1
Sclerosing cholangitisD015209EFO_0004268K83.011————1
Immunoglobulin g4-related diseaseD000077733—D89.841————1
Wiskott-aldrich syndromeD014923EFO_0003903D82.01————1
Show 14 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SpondylitisD013166—M46.9————22
Cognitive dysfunctionD060825—G31.84————22
Human influenzaD007251EFO_0007328J11.1————22
Covid-19D000086382—U07.1————22
Hemoglobin sc diseaseD006450EFO_1001797D57.2————11
Hemoglobin c diseaseD006445—D58.2————11
HemorrhageD006470MP_0001914R58————11
Blood coagulation disordersD001778EFO_0009314D68.9————11
Blood platelet disordersD001791——————11
Hemorrhagic disordersD006474—D69.9————11
Show 27 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRituximab
INNrituximab
Description
Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow injection into a vein.
Classification
Antibody
Drug classmonoclonal antibodies: chimeric, tumors as target
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>1L6X:A|IMMUNOGLOBULIN GAMMA-1 HEAVY CHAIN CONSTANT REGION GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL >1L6X:B|Minimized B-domain of Protein A Z34C FNMQCQRRFYEALHDPNLNEEQRNAKIKSIRDDC
Identifiers
PDB1L6X, 2OSL, 4KAQ, 6VJA, 6Y90
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201576
ChEBI ID—
PubChem CID—
DrugBankDB00073
UNII ID4F4X42SYQ6 (ChemIDplus, GSRS)
Target
Agency Approved
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
931
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Q13963
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Rituxan – Biogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Rituxan – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Ruxience – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Rituximab
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Riabni, Rituxan, Rituxan hycela, Ruxience, Truxima
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
221,913 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use